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OBJECTIVES: Two billion people worldwide have been infected
with hepatitis B virus and approximately 400 million present
chronic disease. Part of chronically infected patients with HBV
develop cirrhosis and liver failure. Two strategies are adopted for
treatment of chronic hepatitis B: a) use of interferon (conven-
tional and pegylated) for a limited timeframe and b) use of
nucleoside/tide analogs for a determined period. This analysis
aims to assess the Incremental cost-utility ratio for peginterferon-
alfa-2a (40 KD) versus lamivudine, for treatment of HBeAg-
positive and HBeAg-negative patients with hepatitis B, from the
perspective of the National Health Service. METHODS: A
Markov model was used to estimate the clinical and economic
impact of the incorporation of peginterferon-alfa-2a (40 KD).
Clinical stages were based on liver histology, cirrhotic decompen-
sation, liver cancer and liver transplantation. Costs were esti-
mated based on resource utilization described in a Delphi panel
with experts. Response and seroconversion rates with peginter-
feron alfa-2a (40 KD) were 36% for HBeAg-negative, and 32%
for HBeAg-positive patients. For lamivudine, rates were 23%
and 19%, respectively. Data concerning the quality-of-life were
extracted from the international literature, due to the lack of
local data. A lifetime horizon was assumed. RESULTS: The ICER
(peginterferon-alfa-2a vs. lamivudine) was R$ 20,192 HBeAg-
negative patients, and R$ 33,749 for HBeAg-positive patients,
assuming a discount rate of 3%. A probabilistic sensitivity analy-
sis was conducted using second-order Monte Carlo simulation.
Tested parameters were costs per stage, treatment costs, discount
rate, and responsiveness to treatment. The 95% conﬁdence inter-
val for the ICER ranged from R$ 12,275 to R$ 35,048 for
HBeAg-negative patients, and R$ 17,771 to R$ 67,430 for
HBeAg-positive patients. CONCLUSION: The study suggests
that therapy with peginterferon-alfa-2a (40 KD) has a robust and
favorable cost-utility ratio in the Brazilian public health system
for both serological proﬁles.
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OBJECTIVES: WHO estimates suggests that there are nearly
38,6 millions HIV/AIDS infected persons worldwide. Some epi-
demiological data suggests around 30% of HIV-infected patients
are also infected by HCV, what would lead to 12 million patients
co-infected with HIV and HCV. Recently, a multicenter, random-
ized controlled trial (APRICOT Torriani et al. 2004) has demon-
strated the efﬁcacy of alphapeginterferon-2a (40KD) + ribavirin
(PEG + RBV) treatment and its superiority to alphainterferon-
2a + ribavirin (IFN + RBV) for the treatment of chronic hepatitis
C in HIV-infected patients. However, incremental cost-
effectiveness ratios have not been established yet for this group of
patients for the private payer perspective in Brazil. METHODS:
A cost-utility analysis was conducted attempting to estimate
costs and outcomes in long term timeframe for PEG + RBV,
IFN + RBV and no speciﬁc treatment for co-infected patients. To
project the disease path, a markov model based on published
literature was constructed. Clinical practice and medical resource
utilization was assessed by a Delphi panel with Brazilian experts.
Both costs and outcomes were discounted at a 3% annual rate.
Payer perspective was adopted regarding direct costs for a life-
time perspective. The model was submitted to a univariate and a
probabilistic sensitivity analysis, beyond Monte Carlo second-
order simulation, to evaluate uncertainties on ICER estimates.
RESULTS: The ICER for the treatment with PEG + RBV com-
pared with IFN + RBV was R$36,645 per QALY with a 95%
conﬁdence interval between R$22,504 to R$64,175. The ICER
for the treatment with PEG + RBV compared with no speciﬁc
treatment was R$28,912 per QALY and the 95% conﬁdence
interval between R$18,768 to R$50,572. CONCLUSION: The
study results suggest that the treatment with alfapeginterferon-2a
(40 KD) can be considered a cost-effective alternative, as it
improves quality and quantity of life regarding other options and
it offers an incremental cost-effectiveness ratio robust and accept-
able for the private payer in Brazil.
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OBJECTIVES: The purpose of this study was to evaluate the
affordability of Antimalarial Drugs using real world data from
private pharmacies, missionary and government hospitals in
Benin city, Nigeria. METHODS: The mean  SD of prices that
patients prescribed Antimalarials in Benin city pay for a standard
regimen when they have malaria was collected from private
pharmacies, missionary and government hospitals. Minimum
wage was obtained directly from the least paid unskilled govern-
ment workers.The data was used to develop a stochastic monte
carlo model that calculates affordability of an Antimalarial drug
(in days’ wages). Two markov models that use 2007 data to
project prices of antimalarial drugs and monthly minimum wages
into the future using inﬂation rates, prices of antimalarials, per-
centage increase in wages and a ﬁxed discount rate of 5% were
also built. Results of the markov models serve as inputs for the
monte carlo simulations so that affordability can thus be pro-
jected into the future for the next 10 years. All three models
reported 1000 observations averaged over 10 repeated simula-
tions. RESULTS: Branded Antimalarial drugs were less afford-
able compared to the lowest priced generic versions (p < 0.0001).
Branded chloroquine tablets were 290% more expensive than the
unbranded and the least paid unskilled government worker
would need to spend about 20 days’ wages to treat malaria with
artemether 80 mg/ml injection. Antimalarials from missionary
and government hospitals were not necessarily more affordable
than those bought in private pharmacies.Peadiatric dihydroarte-
misinin 160 mg/80 ml may become 182% less affordable in 2012
and 226% less affordable by 2017 (p < 0.0001). All Antimalari-
als studied exhibited a similar trend. Sensitivity analyses showed
that these ﬁndings were robust. CONCLUSION: Unless deliber-
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ate public health policies address the affordability of antimalari-
als; it is unlikely that there will be any reduction in malaria
morbidity and mortality in the poor.
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OBJECTIVES: To evaluate the cost-effectiveness of implement-
ing a universal infant 7-valent pneumococcal conjugate vaccine
(PCV7) programme in the Irish health care setting. METHODS:
A model was constructed to follow a cohort of vaccinated and
unvaccinated individuals from birth over a 10 year period. The
number of life years gained (LYG) from the vaccination pro-
gramme was the primary outcome. The model was constructed
using MS Excel and was run in 6 monthly cycles with the excep-
tion of the ﬁrst year of age, which was divided into three age
bands: 0–2 months, 2–6 months and 6–12 months. Incidence
data, vaccine efﬁcacy and background mortality were based on
national data and/or published evidence. A cost of illness esti-
mate for each pneumococcal infection was determined using
decision tree analysis that considered direct costs only. The
reduction in events that would be associated with PCV7 vacci-
nation and the mortality and cost resulting from these events
were analysed. In a separate sub-model the effect of herd immu-
nity was investigated where it was assumed that indirect protec-
tion would be conferred on the unvaccinated adult population
for a period of one year. RESULTS: Implementing a PCV7 vac-
cination programme in Ireland in a birth cohort of 61,000 infants
would be expected to prevent 7,703 cases of pneumococcal
related infections over 10 years, resulting in savings of €2.05
million, increasing to €4.6 million if the effect of herd immunity
is included. The baseline ICER is €98,279/LYG which reduces to
€3,162/LYG when the effect of herd immunity is included. CON-
CLUSION: Universal infant pneumococcal conjugate vaccina-
tion could be considered highly cost-effective in the Irish health
care setting from a health care payers perspective, if viewed in
terms of the herd immunity effect. The results of this study have
positive ramiﬁcations for countries in the early stages of health
technology assessment.
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OBJECTIVES: To understand the infrastructure for HLA-
B*5701 screening within the UK and establish the direct cost of
correctly screening patients. METHODS: Presence of the HLA-
B*5701 allele is associated with predisposition for hypersensitiv-
ity to abacavir (KivexaTM, GSK). Some HIV clinicians routinely
screen patients for HLA-B*5701 prior to prescribing abacavir.
The characteristics and relative costs of available screening
methods are therefore integral to the impact of screening on
cost-effectiveness of abacavir in practice. Yet this information is
poorly understood. No deﬁnitive reference cost is available and
screening is provided by many laboratory services, to varying
speciﬁcations and at different cost. Obtaining robust data there-
fore required a creative approach. Extensive planned research
with clinicians and the sales force informed the content and
structure of the audit. Interviews were conducted with 25 major
HIV centres (currently screening patients for HLA-B*5701 prior
to initiation of abacavir therapy), and an advisory board with
expert panellists was undertaken during 2006. Methodologies
used by different laboratories were explored (with laboratory
personnel if necessary) to determine whether screening of sufﬁ-
cient resolution was provided. RESULTS: The audit found three
regional networks of laboratories providing genetic screening
services to hospitals on a local and national basis. Hospitals
routinely accessed different laboratories for different clinical
services. Result turnaround times varied from 5 to 14 days,
although most laboratories could provide an immediate (2 hour)
service if required. The cost of screening varied between 35–90
GBP. Costs were minimised in larger laboratories predominantly
through using the latest technologies, batching samples, short
transport distances and the use of blood sample aliquots already
extracted for other tests. CONCLUSION: UK HIV clinicians
have routine access to screening technologies for 4-digit resolu-
tion of HLA-B*5701 that are affordable, quality assured and
rapid. The impact of this information on the cost effectiveness of
abacavir is the subject of ongoing research.
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OBJECTIVES: To estimate from the national database of hos-
pital admissions in 2005, the economic burden in France of
febrile neutropenia (FN) associated with myelosuppressive che-
motherapy. METHODS: In France, public and private hospital
admissions are recorded in administrative databases that gen-
erate Diagnosis Related Groups (DRGs), ICD10 diagnosis and
procedure codes. Admissions with FN were extracted with
codes combining cancer, chemotherapy, and drug-induced neu-
tropenia. These were then categorized into those with a prin-
cipal diagnosis of FN, those in which FN prolonged length of
stay, and those where planned treatments were cancelled due to
FN. The costs of admissions to public hospitals were obtained
from an annual study of a sample group of institutions. This
study is also used to generate charges to the payer (ofﬁcial
DRG tariffs). Costs in private clinics were estimated with the
2004 reimbursement database, to which medical fees were
added. Charges to the health care system were estimated with
the ofﬁcial 2007 DRG tariffs. RESULTS: In 2005, the total
number of patient admissions meeting selection criteria was
38,266 i.e. 3% of all admissions for chemotherapy. Of these,
41% were due to FN, 56% were prolonged hospitalizations
because of FN and 3% were procedures cancelled due to FN.
In public hospitals, the mean cost per admission due to FN was
€3636 (n = 13,923), mean charge was €3565. In private hospi-
tals, this cost was €1930 per admission (n = 1517). For inpa-
tient admissions to public hospitals alone (n = 9444), the mean
cost was €5030, mean charge €4931. Total cost to the payer
for public and private admissions was €54 million i.e. 3% of
the total cost for chemotherapy in France. CONCLUSION:
Administrative databases can be used to estimate the economic
burden of FN, a frequent complication of chemotherapy. They
could be a relevant tool for studying the potential cost savings
derived from appropriate preventive use of colony-stimulating
factors.
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